KRAS and colorectal carcinoma: Although accumulating evidence indicates that these molecular characteristics (including MSI, CIMP, and BRAF/KRAS mutation status) have diagnostic, therapeutic, and prognostic significance in CRC [20–22], their incidences, especially those of MSI, BRAF mutation, and CIMP, vary considerably among different ethnic groups [8, 22, 23].